Australia markets closed

Monte Rosa Therapeutics, Inc. (GLUE)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
5.54+0.04 (+0.73%)
At close: 04:00PM EDT
5.54 0.00 (0.00%)
After hours: 07:58PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 275.85M
Enterprise value 89.47M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.54
Enterprise value/revenue N/A
Enterprise value/EBITDA -0.65

Trading information

Stock price history

Beta (5Y monthly) 1.45
52-week change 320.43%
S&P500 52-week change 325.01%
52-week high 38.84
52-week low 32.44
50-day moving average 36.39
200-day moving average 35.51

Share statistics

Avg vol (3-month) 3134.28k
Avg vol (10-day) 3118.28k
Shares outstanding 550.15M
Implied shares outstanding 650.15M
Float 823.65M
% held by insiders 10.86%
% held by institutions 198.54%
Shares short (28 Mar 2024) 41.68M
Short ratio (28 Mar 2024) 411.03
Short % of float (28 Mar 2024) 46.25%
Short % of shares outstanding (28 Mar 2024) 43.36%
Shares short (prior month 29 Feb 2024) 41.84M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-27.72%
Return on equity (ttm)-60.07%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -137.09M
Net income avi to common (ttm)-135.35M
Diluted EPS (ttm)-2.63
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)232.41M
Total cash per share (mrq)4.64
Total debt (mrq)46.04M
Total debt/equity (mrq)25.68%
Current ratio (mrq)5.07
Book value per share (mrq)3.58

Cash flow statement

Operating cash flow (ttm)-43.8M
Levered free cash flow (ttm)-55.47M